ULRIKE FUHRMANN
No ORCID on file
· 23 papers in corpus
article
2014
Is it feasible to deliver anastrozole (ATZ), an aromatase inhibitor (AI), by a vaginal polymer-based drug delivery system in the cynomolgus monkey (Macaca fascicularis) to describe the pharmacokinetic profile? The present study showed the e…
article
2012
Endometriosis (EMS) is a chronic, estrogen-dependent inflammatory disease characterized by growth of endometrial tissue outside the uterine cavity. Symptoms in EMS patients include severe pelvic pain, dysmenorrhea, dyspareunia and infertili…
article
2012
We identified differentially expressed genes comparing peritoneal endometriosis lesions (n = 18), eutopic endometrium (n = 17), and peritoneum (n = 22) from the same patients with complete menstrual cycles using microarrays (54 675 probe se…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2010
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
other
2009
Progesterone receptor modulators (PRMs) play an important role in women's health. They are widely used in oral contraception or hormone therapy, and provide an attractive treatment approach for gynecological disorders such as uterine leiomy…
article
1997
To shed light on the molecular mechanisms involved in the pathogenesis of uterine leiomyomas, transcript levels of the immediate early genes c-fos, c-myc, and c-jun and of the estrogen receptor (ER) and progesterone receptor (PR) were deter…